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INVITED COMMENTARY
Pretreatment with dextran 1 makes dextran 40 therapy saferKarl-Gösta Ljungström, MD, PhD, Stockholm, SwedenAt a meeting held in July 2005, the Blood Products
Advisory Committee of the US Food and Drug Adminis-
tration (FDA) addressed the problem of serious and life-
threatening anaphylactoid reactions induced by intrave-
nous dextran solutions (dextran-induced anaphylactoid[ic]
reactions, DIAR). The FDA has recently become aware
that pretreatment with dextran 1 to reduce the risk of
DIAR is rarely being followed by surgeons and anesthesi-
ologists, especially those just out of training, because the
package inserts of clinical dextrans sold in the United States
today do not contain any information on the clinical benefit
of dextran 1. The purpose of this editorial is to review
hapten inhibition by dextran 1, a routine that has resulted
in a dramatic 35-fold reduction of severe DIAR in other
countries.
Dextrans are composed of long chains of glucose mol-
ecules linked by 1-6 bonds. These solutions have been
licensed for almost 60 years, and although many newer
colloids have been introduced, dextrans still hold a place for
routine use in vascular and plastic surgery. The reason is
that dextrans have advantageous rheologic properties—
they moderate platelet function and are antithrombotic—
that other colloids do not possess. Today, dextran solutions
are utilized by vascular surgeons to reduce the risk of
postoperative stroke in carotid endarterectomy patients1
and by plastic and reconstructive surgeons to reduce the
risk of occlusion of microvascular anastomoses.2
Allergic reactions are seen with both naturally occur-
ring and artificial colloids administered intravenously. The
early dextrans of the 1940s frequently caused allergic reac-
tions. Despite introduction in the 1950s of less-branched
Table I. Dextran-induced anaphylactoid(ic) reaction in Sw
1983 to 1992
Grades of severity Characteristic symptoms
I Skin symptoms (flush, erythema, urtic
Lumbar pain
II Mild to moderate hypotension (systoli
BP 40-60 mm Hg, depending on
duration)
Gastrointestinal disturbances
Respiratory distress
III Severe hypotension, shock
Bronchospasm
IV Cardiac and/or respiratory arrest
V Fatal reaction
Total
DIAR, Dextran-induced anaphylactoid(ic) reaction.
*During 1975-1979, 647,756 units of clinical dextrans were sold to hospit
†During 1983-1992, 1.2 million units of dextran 1 were sold, correspondi
before the first unit of clinical dextran.6
1070dextran molecules and a much lower incidence of adverse
reactions, this view continues to prevail in some countries.
Two different mechanisms in DIAR have been demon-
strated: mild, anaphylactoid, non-antibody-dependent re-
actions, and severe anaphylactic reactions in patients with
high titers of preformed dextran-reactive antibodies
(DRA).3 These severe reactions can be triggered by small or
even minute (0.5 to 1.0 mL) volumes of dextran and are
caused by large immune complexes formed from dextran
molecules and DRA, predominantly immunoglobulin (Ig)
G.4 These reactions activate platelets, as well the coagula-
tion and complement systems, resulting in allergic symp-
toms. Respiratory and circulatory derangement is also seen
with increasing grades of severity, as summarized in Table I.
It should be pointed out that IgE, mast cells, and hista-
mine, among others, are not involved in these type III
anaphylaxis reactions. Clinical dextrans are nonimmuno-
genic, and previous exposure to dextrans is not a risk factor.
Rather, DRA are thought to represent cross-reactive anti-
bodies against polysaccharides in encapsulated bacteria7 or
antibodies against native, “wild” dextran, such as in cane
sugar.
Reports of adverse drug effects in national pharmaco-
vigilance databases may underestimate the true incidence of
side effects. The incidence of adverse effects following
colloid administration, even in prospective trials, may be
misleading if the incidence is only calculated in relation to
the number of units of colloids administered. This is be-
cause adverse reactions are generally seen only when the
first unit is given, and it is common to give several units to
each patient.
n, 1975 to 1979, and during postmarketing surveillance,
DIAR (n)
1975 to 1979
(without dextran 1)
1983 to 1992
(with dextran 1)
61 78
94 44
78
1/2,000*
12
1/70,000†44 4
23 1
300 139
ics in Sweden, corresponding to 0.3 million dextran-treated patients.5
the same number of dextran-treated patients, since dextran 1 is only givenede
aria)
c
al clin
ng to
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made mandatory in 1974. This caused a considerable in-
crease in the total number of adverse events reported but no
increase in the number of reports on fatal adverse events,
indicating that these were already being reported to a high
degree. In a study of adverse reactions to dextrans in
Sweden for 1970 to 1979, reports sent to regulatory bod-
ies, insurance companies, and the manufacturer were col-
lected and analysed. Complete hospital records were avail-
able in 90% of the cases. For the period 1975 to 1979, the
calculated incidence of severe DIAR was one in 2000.5
The idea to use hapten inhibition was suggested early
on by Kabat et al,8 who demonstrated in vitro that the
combining site of DRA would bind to approximately five
glucose molecules of the dextran chain. It was later shown
in animal experiments that by injecting small fragments of
dextran (ie, dextran 1), the combining sites of DRA could
be blocked without eliciting a reaction.9 Demonstrating
the efficacy of this method in humans was a formidable task,
given an incidence of only one reaction in 2000 treated
patients. Between 1978 and1982, a series of multicenter
studies comprising 130,000 patients were conducted in
three Scandinavian countries, Germany, and Switzerland.
The 1.5-g dose of dextran 1 used in the beginning proved
too small; however, doubling the dose significantly reduced
the incidence of severe DIAR compared with the first dose.
Reactions to dextran 1 itself were of low frequency, mainly
isolated mild skin reactions or short-lasting episodes of
bradycardia with or without hypotension.10-13
Shortly thereafter, dextran 1 was approved in 15 coun-
tries, including the United States, where it was introduced
in 1984. Postmarketing surveillance has continued during
the 22 years since approval both in Sweden and worldwide,
and the results have been published twice.6,14 Overall, the
same protective effect achieved in the prospective studies
has been observed in clinical practice—a 35-fold reduction
in severe DIAR (an incidence of 1 in 70,000 exposures)
compared with the 1975 to 1979 historical control data
(Table I). With 8 million doses of dextran 1 distributed
worldwide, only two fatal cases of DIAR have been re-
ported after clinical dextran administration in patients pre-
treated with dextran 1, a 90-fold reduction!
The basic principles for administering dextran 1 are
summarized in Table II. Of note, pretreatment with 3 g of
dextran 1 cannot completely eliminate the risk for severe
DIAR, since occasional patients with extremely high titres
of DRA still react, although the reactions in most of these
cases are attenuated. In addition, pretreatment with dex-
tran 1 does not prevent mild, anaphylactoid, nonantibody-
dependent reactions. Still, with dextran 1 pretreatment, the
incidence of severe adverse reactions to dextran in Sweden
today is lower than the corresponding incidence reported
for human serum albumin in the only two existing prospec-
tive studies on adverse reactions to intravenous col-
loids.15,16
Use of hypertonic saline/dextran to resuscitate trauma
patients in the field and in-hospital is a fascinating new
therapy. This solution has been widely used in Europe(20,000 units sold) without any reports of DIAR, even
though dextran 1 is rarely preinjected. Some have proposed
that absence of reports of DIAR in patients with hemor-
rhagic shock is due to the excessive release of endogenous
catecholamines, although there is no scientific evidence for
this. In any event, in the emergency setting, the risk of
severe DIAR (1/2000) is insignificant compared with the
risk of increased mortality from prolonged shock.
In summary, severe DIAR is a condition that can be
virtually prevented by the safe and simple principle of
hapten inhibition with dextran 1 pretreatment. This
method has been used in northern Europe for 20 years
with 8 million exposures and has resulted in a 35-fold
reduction of severe DIAR and a 90-fold reduction of fatal
reactions, making dextran at least as safe as albumin and
starches.
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